crane(CR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CR crane

Post-Mkt 09-08 18:52:24 EDT

202.65

-2.04

-1.00%

盘后202.65

+0.000.00%

16:10 EDT

High206.86	Low202.34	Vol282.80K
Open204.60	D1 Closing204.69	Amplitude2.21%
Mkt Cap11.67B	Tradable Cap9.88B	Total Shares57.60M
T/O57.69M	T/O Rate0.58%	Tradable Shares48.76M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CR","market":"US","secType":"STK","nameCN":"crane","latestPrice":202.65,"timestamp":1788897600000,"preClose":204.69,"halted":0,"volume":282797,"hourTrading":{"tag":"盘后","latestPrice":202.65,"preClose":202.65,"latestTime":"16:10 EDT","volume":3438,"amount":696708.05274,"timestamp":1788898204930,"change":0,"changeRate":0,"amplitude":0.003208},"delay":0,"changeRate":-0.00996629048805507,"floatShares":48764858,"shares":57596887,"eps":5.729591,"marketStatus":"Post-Mkt","change":-2.04,"latestTime":"09-08 18:52:24 EDT","open":204.6,"high":206.86,"low":202.34,"amount":57687522,"amplitude":0.022082,"askPrice":206.6,"askSize":9,"bidPrice":202.31,"bidSize":3,"shortable":3,"etf":0,"ttmEps":5.729591,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1788912000000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"NYSE","adjPreClose":204.69,"dividendRate":0.00491,"postHourTrading":{"tag":"盘后","latestPrice":202.65,"preClose":202.65,"latestTime":"16:10 EDT","volume":3438,"amount":696708.05274,"timestamp":1788898204930,"change":0,"changeRate":0,"amplitude":0.003208},"volumeRatio":0.651431,"impliedVol":0.3187,"impliedVolPercentile":0.3705},"requestUrl":"/m/hq/s/CR/tweets","defaultTab":"tweets","newsList":[{"id":"2665323631","title":"E KOCREF CR-REIT Receives Clean Audit Opinions and Posts Stable Earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=2665323631","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665323631?lang=en_us&edition=fundamental","pubTime":"2026-09-08 15:45","pubTimestamp":1788853535,"startTime":"0","endTime":"0","summary":"E KOCREF CR-REIT ( ($KR:088260) ) has shared an announcement. E KOCREF CR-REIT reported consolidated and separate financial statements for the curr...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/e-kocref-cr-reit-receives-clean-audit-opinions-and-posts-stable-earnings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/e-kocref-cr-reit-receives-clean-audit-opinions-and-posts-stable-earnings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["YLDW","IQRA","DFRA","BPRE","PSCF","IVRA","RJMG","RNTY","MDIV","CR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664084160","title":"Crane Director James L. L. Tullis Disposes of 400 Shares Worth $82,150","url":"https://stock-news.laohu8.com/highlight/detail?id=2664084160","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664084160?lang=en_us&edition=fundamental","pubTime":"2026-09-03 04:47","pubTimestamp":1788382078,"startTime":"0","endTime":"0","summary":"Crane director James L. L. Tullis disposes of 400 shares worth $82,150Crane Co director James L. L. Tullis sold 400 common shares on Aug. 31, 2026 at USD 205.38.Directly held stake fell to 5,021 share","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260902:nNDL8Bn8RG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Crane Director James L. L. Tullis Disposes of 400 Shares Worth $82,150","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4161","CR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664964498","title":"CR Sanjiu Gets Registration Approval for 1 Billion Yuan Bonds","url":"https://stock-news.laohu8.com/highlight/detail?id=2664964498","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664964498?lang=en_us&edition=fundamental","pubTime":"2026-09-02 13:56","pubTimestamp":1788328603,"startTime":"0","endTime":"0","summary":"China Resources Sanjiu Medical & Pharmaceutical  subsidiary Kun Pharmaceutical obtained approval from China's interbank market regulator to register 1 billion yuan in medium-term notes.The two-year registration allows Kun Pharmaceutical to issue debt in installments, according to a Wednesday filing with the Shenzhen bourse.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["000999","BK0010","BK0175","BK0239","BK0188","BK0183","CR","BK0196","BK0060","BK0185","BK0028","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664853718","title":"Crane : Deutsche Bank Cuts Target Price to $240 from $248","url":"https://stock-news.laohu8.com/highlight/detail?id=2664853718","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664853718?lang=en_us&edition=fundamental","pubTime":"2026-09-01 19:05","pubTimestamp":1788260715,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260901:nAQN2MHI6S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CR","BK4161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664839144","title":"CR Double-Crane Pharma Gets Registration Certificate for Oxcarbazepine Tablets","url":"https://stock-news.laohu8.com/highlight/detail?id=2664839144","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664839144?lang=en_us&edition=fundamental","pubTime":"2026-09-01 15:27","pubTimestamp":1788247666,"startTime":"0","endTime":"0","summary":"China Resources Double-Crane Pharmaceutical  received a drug registration certificate from the National Medical Products Administration for its oxcarbazepine tablets, according to a Shanghai bourse filing on Tuesday.The certificate was received through subsidiary China Resources Double-Crane Xiangzhong Pharmaceutical .The drug is used as treatment for primary generalized tonic-clonic seizures and partial seizures, with or without secondary generalized seizures, for children and adults.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0175","BK0239","BK0028","CR","BK0010","BK0188","600062","BK0185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664836727","title":"U.S. Research Roundup-Autodesk, Hubspot, Oracle","url":"https://stock-news.laohu8.com/highlight/detail?id=2664836727","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664836727?lang=en_us&edition=fundamental","pubTime":"2026-09-01 15:06","pubTimestamp":1788246377,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Autodesk, Hubspot, OracleSept 1 (Reuters)-Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Autodesk, Hubspot an","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260901:nL4N44T0K8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMAT","RDVI","SAAPLmain","BWA","CSR","VT","CR","CRWD","DELL","ADBE","DASH","DRI","ABNB","ACRS","TXG","A","DK","WLDR","BLSM","CAPR","CSCO","DBI","WNDR","BKNG","CTRE","AAPL","DUOL","BXSL","BAH","CPT","DHR","ANET","BXP","DASX","ARCC","ASMB","CDP","CSCS","BBIO","ATEN","BKNU","ANNX","CLOD","AKAM","EGP","VGT","ADSK","COHR","BILL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664833005","title":"E KOCREF CR-REIT Seeks Proxies Ahead of AGM as It Maintains High Dividend Payouts","url":"https://stock-news.laohu8.com/highlight/detail?id=2664833005","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664833005?lang=en_us&edition=fundamental","pubTime":"2026-09-01 13:51","pubTimestamp":1788241919,"startTime":"0","endTime":"0","summary":"An announcement from E KOCREF CR-REIT ( ($KR:088260) ) is now available. E KOCREF CR-REIT has called its 41st regular shareholders’ meeting for 16 ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/e-kocref-cr-reit-seeks-proxies-ahead-of-agm-as-it-maintains-high-dividend-payouts?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/e-kocref-cr-reit-seeks-proxies-ahead-of-agm-as-it-maintains-high-dividend-payouts?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IQRA","DFRA","YLDW","RJMG","CR","PSCF","MDIV","BPRE","RNTY","IVRA","REIT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663075740","title":"CR Mixc Lifestyle's Cash Flow, Expected Dividend Growth Reinforces Core Holding Status","url":"https://stock-news.laohu8.com/highlight/detail?id=2663075740","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663075740?lang=en_us&edition=fundamental","pubTime":"2026-08-31 16:53","pubTimestamp":1788166380,"startTime":"0","endTime":"0","summary":"0853 GMT - China Resources Mixc Lifestyle Services' robust cash flow and likely 2026 dividend-per-share growth reinforces its status as a long-term holding for resilient, recurring returns, Citi analysts say in a note. The Hong Kong-listed property-management company's growth is likely to be driven by its strong execution and commercial strength, with a majority of its malls ranked high locally, they write. The analysts expect CR Mixc Lifestyle's earnings to grow more than 10% over 2026-2028 as same-store sales gain, its mall network expands and it improves its efficiency and cost savings. Citi raises its target price to 53.30 Hong Kong dollars from HK$52.13 and maintains a buy rating. Shares close 3.3% lower at HK$39.10.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0082770016.USD","LU0456827905.SGD","BK1583","CR","BK1229","LU0082770016.SGD","BK1542","LU0620787316.HKD","LU0164939612.USD","BK1258","LU0456846285.SGD","01209","LU0051755006.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663017341","title":"Stronger-Than-Expected Q2 Results And Higher EPS Guidance Might Change The Case For Investing In Crane (CR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2663017341","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663017341?lang=en_us&edition=fundamental","pubTime":"2026-08-29 18:20","pubTimestamp":1787998844,"startTime":"0","endTime":"0","summary":"In its recently reported Q2 results, Crane NXT posted a 22% year-on-year revenue increase, beat analysts’ EPS estimates and full-year EPS guidance, and raised its Adjusted EPS outlook on the back of strong first-half performance.\nThe reaction highlighted that, even with upgraded guidance, investor expectations appeared to be set higher than consensus, underscoring how demanding the market’s performance bar has become for Crane NXT.\nNext, we’ll examine how Crane NXT’s raised full-year...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/3072000-choice2-main-header/1585186655182","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/3072000-choice2-main-header/1585186655182"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/capital-goods/nyse-cr/crane/news/stronger-than-expected-q2-results-and-higher-eps-guidance-mi","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/capital-goods/nyse-cr/crane/news/stronger-than-expected-q2-results-and-higher-eps-guidance-mi","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["DECU","RGLO","JOYT","BK4161","ARTY","PMDE","QTOC","VGFPF","AIPO","AGIX","VTHR","FEBU","VOTE","GXDW","CR","CHAT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661695272","title":"Press Release: InnoCare Reports 2026 Interim Results, Sustained Profitability and Key Milestones Achieved","url":"https://stock-news.laohu8.com/highlight/detail?id=2661695272","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661695272?lang=en_us&edition=fundamental","pubTime":"2026-08-24 22:32","pubTimestamp":1787581920,"startTime":"0","endTime":"0","summary":"BEIJING, Aug. 24, 2026  -- InnoCare Pharma , a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced the interim results and business highlights for the six months ended 30 June 2026.InnoCare delivered robust revenue growth and strengthened profitability in the first half of 2026, driven by strong commercial execution and global business development collaborations. In the first half of 2026, the Company's revenue grew by 55.5% year-on-year to RMB 1.1 billion, and profit reached RMB 239.7 million, a turnaround from a loss in the same period last year. These results reflect the successful implementation of the Company's strategy driven by innovation, commercialization and globalization.In the first half of 2026, InnoCare continued to accelerate innovation, achieving a series of key milestones.-- 1 NDA approval: Orelabrutinib was approved in Australia.-- 2 NDA acceptances: The NDA applications for orelabrutinib in primary. immune thrombocytopenia  a","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0347712357.USD","BK4211","BK4161","IND","BK4567","LU1093756325.SGD","ORR","LU1093756168.USD","LU1721428933.USD","LU2413666426.HKD","BK4121","IE00BFXG0V08.USD","BK4077","BK4199","09969","BK4195","PFS","BK4588","LU2211817866.USD","IE00B5TLWC47.USD","BK4548","BK1574","BK4585","CR","LU2413666699.HKD","IE00BYQQ9H92.USD","SLE","BK1161","BK4533","MTD","ITP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661410992","title":"Press Release: Antengene Announces 2026 Interim Results: Achieves First","url":"https://stock-news.laohu8.com/highlight/detail?id=2661410992","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661410992?lang=en_us&edition=fundamental","pubTime":"2026-08-24 09:00","pubTimestamp":1787533200,"startTime":"0","endTime":"0","summary":"SHANGHAI and HONG KONG, Aug. 23, 2026 /PRNewswire/ -- Antengene Corporation Limited (\"Antengene\", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0963586101.USD","PYZ","XAR","BK4006","BK1191","LU2065731478.USD","BK4022","BK4585","IE00B66KJ199.SGD","BK4232","BK4588","COAL","06996","IE0031619046.USD","R","ORR","HCC","BK1583","BK4099","IE00B19Z4B17.USD","TM","IE00B7SZL793.SGD","03160","CRS","BK4187","BK4604","CR","BK4555","BK1574","BK4161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660487181","title":"UroGen Submits NDA for UGN-103, an Investigational Treatment of Recurrent LG-IR-NMIBC","url":"https://stock-news.laohu8.com/highlight/detail?id=2660487181","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660487181?lang=en_us&edition=fundamental","pubTime":"2026-08-17 20:00","pubTimestamp":1786968000,"startTime":"0","endTime":"0","summary":"PRINCETON, N.J., Aug.  17, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and spec","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/17/3346054/0/en/urogen-submits-nda-for-ugn-103-an-investigational-treatment-of-recurrent-lg-ir-nmibc.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0124384867.USD","IR","LU0256863902.USD","SG9999001440.SGD","LU0417517546.SGD","BK4161","BK4588","CR","BK4585","LU1978683503.SGD","LU0256863811.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659216081","title":"Crane Director James L. L. Tullis Sells 614 Shares for $138,150","url":"https://stock-news.laohu8.com/highlight/detail?id=2659216081","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659216081?lang=en_us&edition=fundamental","pubTime":"2026-08-15 04:51","pubTimestamp":1786740676,"startTime":"0","endTime":"0","summary":"Crane director James L. L. Tullis sells 614 shares for $138,150Crane Co director James L. L. Tullis sold 614 common shares on Aug. 13, 2026 at USD 225.The sale cut his directly held stake to 5,421 sha","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nNDL7GKpTZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Crane Director James L. L. Tullis Sells 614 Shares for $138,150","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4161","CR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659912921","title":"Press Release: Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2659912921","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659912921?lang=en_us&edition=fundamental","pubTime":"2026-08-15 04:30","pubTimestamp":1786739400,"startTime":"0","endTime":"0","summary":"$7.1 Million in revenue for the first nine months of fiscal 2026 from commercial sales of LYMPHIR (R)$17 million in cash and cash equivalents as of June 30, 2026Expanded LYMPHIR commercial and medical","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PXI","BK4139","BK4007","R","BK4022","BK4232","BK4161","ORR","CTOR","CR","PR","CTXR","BK4213","FXN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659129230","title":"Press Release: Citius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2659129230","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659129230?lang=en_us&edition=fundamental","pubTime":"2026-08-15 04:30","pubTimestamp":1786739400,"startTime":"0","endTime":"0","summary":"$7.1 million in revenue for the first nine months of fiscal 2026 as the LYMPHIR(R) launch progressesStrong institutional demand drives growth in total vials ordered and number of institutions ordering","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PR","BK4588","BK4604","BK4232","CR","CTOR","LU1169589451.USD","BK4560","BK4139","BK4555","LU0348723411.USD","BK4007","BK4585","BK4213","BK4161","PXI","03160","DT","BK4099","R","FXN","ORR","LU1169590202.USD","BK4023","TM","BK4022","CTXR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659141513","title":"Moleculin Biotech Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of Pivotal MIRACLE Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2659141513","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659141513?lang=en_us&edition=fundamental","pubTime":"2026-08-14 20:30","pubTimestamp":1786710600,"startTime":"0","endTime":"0","summary":"Positive interim MIRACLE data showed complete remission rates three times higher than control in relapsed/refractory AMLMIRACLE trial advancing toward planned 90-patient enrollment milestone in Septem","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/14/3345316/0/en/moleculin-biotech-reports-second-quarter-2026-financial-results-and-highlights-continued-advancement-of-pivotal-miracle-trial.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4581","BK4588","BK4585","CR","BK4161","XBI","BK4139","MBRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659162947","title":"Press Release: Caribou Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2659162947","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659162947?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:05","pubTimestamp":1786651500,"startTime":"0","endTime":"0","summary":"clinical trial were presented at the 2026 European Hematology Association.  Annual Meeting. Data presented reinforced vispa-cel is the only. single-dose, off-the-shelf therapy to demonstrate deep and durable. responses on par with autologous CAR-T cell therapies in second-line . large B cell lymphoma . Efficacy and safety data in 2L LBCL. patients who had received a single dose of 80 million optimized vispa-cel. -- Optimized vispa-cel is defined as cells from a donor younger than 30. years old with at least two matched human leukocyte antigen  alleles. between patient and donor. The 27-patient subgroup best represents the. treatment regimen and patient population for Caribou's planned ANTLER-3. -- Caribou previously reached alignment with the U.S. Food and Drug. Administration  regarding its planned ANTLER-3 pivotal phase 3. clinical trial design, which is expected to be a randomized, control","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FBT","LD","MEDX","PFS","BK4230","BK4539","TBXU","GDOC","NVIB","SYNB","BK4022","LFSC","BK4588","CAR","BK4195","CRBU","GNOM","HYLG","IBBQ","BK4585","CR","BK4211","ORR","BK4161","CNCR","IDNA","IBB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658670415","title":"What Crane (CR)'s Acquisition-Fueled Guidance Hike Means For Shareholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2658670415","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658670415?lang=en_us&edition=fundamental","pubTime":"2026-08-10 00:23","pubTimestamp":1786292612,"startTime":"0","endTime":"0","summary":"In late July 2026, Crane Company reported second-quarter 2026 results showing sales rising to US$724.7 million and net income of US$95.9 million, alongside affirming a regular quarterly dividend of US$0.255 per share for payment on September 9, 2026.\nThe company also raised its full-year 2026 sales growth guidance into the mid-20% range, highlighting acquisitions as a key driver of its expanded outlook.\nNow we’ll explore how Crane’s raised full-year sales guidance, driven by acquisitions,...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/3072000-choice2-main-header/1585186655182","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/3072000-choice2-main-header/1585186655182"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/capital-goods/nyse-cr/crane/news/what-crane-crs-acquisition-fueled-guidance-hike-means-for-sh","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/capital-goods/nyse-cr/crane/news/what-crane-crs-acquisition-fueled-guidance-hike-means-for-sh","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["AIPO","QTOC","VTHR","ARTY","CHAT","BK4161","CR","AGIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657154221","title":"UroGen Reports $50.4 Million of ZUSDURI Revenue and Provides Second Quarter 2026 Financial Results and Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2657154221","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657154221?lang=en_us&edition=fundamental","pubTime":"2026-08-05 20:00","pubTimestamp":1785931200,"startTime":"0","endTime":"0","summary":"ZUSDURI generated $50.4 million in revenue in the second quarter of 2026, representing 73% quarter-over-quarter growthOnce issued, new U.S. patent is expected to provide protection into July 2044 for ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/05/3339270/0/en/UroGen-Reports-50-4-Million-of-ZUSDURI-Revenue-and-Provides-Second-Quarter-2026-Financial-Results-and-Highlights.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CR","IXJ","VHT","BK4550","TCAF","NOBL","BK4161","CGCV","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655366963","title":"Moleculin’s MIRACLE R/R AML Trial Reports Positive Interim Data with 37% Blinded CRc in Venetoclax-Failed Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2655366963","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655366963?lang=en_us&edition=fundamental","pubTime":"2026-07-31 20:10","pubTimestamp":1785499800,"startTime":"0","endTime":"0","summary":"Prior venetoclax failure — a setting in which published salvage remission rates are approximately 13% and median survival approximately 2.4 months — shows no adverse impact on blinded composite remiss","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/31/3336762/0/en/Moleculin-s-MIRACLE-R-R-AML-Trial-Reports-Positive-Interim-Data-with-37-Blinded-CRc-in-Venetoclax-Failed-Patients.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CR","BK4161"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cranenxt.com","stockEarnings":[{"period":"1week","weight":-0.0112},{"period":"1month","weight":-0.0824},{"period":"3month","weight":0.0838},{"period":"6month","weight":0.071},{"period":"1year","weight":0.1059},{"period":"ytd","weight":0.1099}],"compareEarnings":[{"period":"1week","weight":0.0011},{"period":"1month","weight":0.0005},{"period":"3month","weight":0.0443},{"period":"6month","weight":0.1455},{"period":"1year","weight":0.1865},{"period":"ytd","weight":0.1294}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Crane NXT, Co. focuses on payment and merchandising technologies. It indents to offer electronic equipment and associated software leveraging extensive, and proprietary core capabilities, including payment verification and authentication, as well as automation solutions, field service solutions, remote diagnostics, and productivity enhancing software solutions. The company is based in Stamford, Connecticut.","yearOnYearQuotes":[{"month":1,"riseRate":0.543478,"avgChangeRate":0.020828},{"month":2,"riseRate":0.717391,"avgChangeRate":0.036902},{"month":3,"riseRate":0.565217,"avgChangeRate":0.013749},{"month":4,"riseRate":0.617021,"avgChangeRate":0.003315},{"month":5,"riseRate":0.638298,"avgChangeRate":0.009155},{"month":6,"riseRate":0.595745,"avgChangeRate":0.009681},{"month":7,"riseRate":0.574468,"avgChangeRate":0.003391},{"month":8,"riseRate":0.340426,"avgChangeRate":-0.01015},{"month":9,"riseRate":0.361702,"avgChangeRate":-0.022223},{"month":10,"riseRate":0.586957,"avgChangeRate":0.009396},{"month":11,"riseRate":0.543478,"avgChangeRate":0.025826},{"month":12,"riseRate":0.608696,"avgChangeRate":0.018097}],"exchange":"NYSE","name":"crane","nameEN":"crane"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.49.0","shortVersion":"4.49.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"crane(CR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest crane(CR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"crane,CR,crane股票,crane股票老虎,crane股票老虎国际,crane行情,crane股票行情,crane股价,crane股市,crane股票价格,crane股票交易,crane股票购买,crane股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"crane(CR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest crane(CR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}